Our Services
Medical Information
Helpful Resources
Published on: 9/24/2026
The latest type 1 diabetes treatments include automated insulin delivery (hybrid closed-loop) systems that pair continuous glucose monitors with smart pumps, ultra-rapid and longer-acting insulin analogs, and teplizumab (Tzield), the first immunotherapy shown to delay the onset of stage 3 disease in people at risk. Emerging options such as stem cell derived islet cell transplants, adjunct medications like metformin or SGLT inhibitors, and next generation sensors are also expanding what is possible beyond insulin alone. Which approach fits depends on your antibody status, glucose patterns, hypoglycemia risk, and access to technology, so there are several important factors to consider below before deciding what to discuss with your care team.
If you are noticing symptoms like excessive thirst, frequent urination, unexplained weight loss, or fatigue, knowing where you stand matters more than any single treatment headline, because timing changes which therapies are even available to you. Take a free, instant, online symptom check to clarify what your symptoms may mean and get guidance on the right next steps.
Last reviewed for medical accuracy: 09/24/2026
Type 1 diabetes (T1D) occurs when the body’s immune system destroys insulin-producing beta cells in the pancreas. Without insulin, blood sugar stays too high, leading over time to complications such as heart disease, nerve damage and kidney problems. While researchers have made important strides, there is currently no proven way to fully “cure” or reverse type 1 diabetes. That said, advances in insulin delivery, glucose monitoring, immune therapies and cell-replacement strategies are transforming day-to-day management—and bringing us closer to one day preventing or reversing the disease.
“Can you reverse type 1 diabetes?” is one of the most common questions patients ask. At present:
In short, we cannot yet reverse type 1 diabetes in the way we might reverse prediabetes or type 2 diabetes through lifestyle alone. However, ongoing research brings hope that future treatments may rebuild or protect insulin-making cells.
Managing T1D today focuses on replicating normal insulin patterns as closely as possible, plus constant glucose monitoring:
Exogenous Insulin Therapy
Continuous Glucose Monitoring (CGM)
Hybrid Closed-Loop Systems (“Artificial Pancreas”)
Researchers are exploring ways to halt the autoimmune attack and rebuild insulin production.
• Immunotherapies
• Beta-Cell Replacement
• Encapsulation Technologies
• Stem-Cell Derived Therapies
• Gene and RNA-Based Strategies
While awaiting breakthroughs, focus on tools and habits that help you live your healthiest life:
• Personalized Nutrition
• Physical Activity
• Technology Adoption
• Mental Health & Support
If you experience worrisome signs—such as unexplained high blood sugars, frequent hypos, extreme thirst or sudden weight loss—you might consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker. This quick tool can help you decide whether to seek urgent care or schedule an appointment with your diabetes team.
Every person’s diabetes is unique. Before making any changes to medication, diet or exercise:
Always remember, managing T1D is a team effort—you, your healthcare providers and your support network. If you ever feel overwhelmed or notice serious symptoms, talk to a doctor right away. Continuous innovation is making this journey easier and safer every year, and one day we may finally answer “can you reverse type 1 diabetes” with a firm yes. Until then, the best path is proactive management, informed decisions and ongoing dialogue with your medical team.
(References)
* Furman BL. Streptozotocin-Induced Diabetic Models in Mice and Rats. Curr Protoc Pharmacol. 2015 Sep 1;70:5.47.1-5.47.20. doi: 10.1002/0471141755.ph0547s70. Epub 2015 Sep 1. PMID: 26331889.
* Sethuram S, Rapaport R. Update: Pediatric Diabetes. J Diabetes. 2020 Oct;12(10):769-771. doi: 10.1111/1753-0407.13033. Epub 2020 Mar 13. PMID: 32166876.
* Castellanos L, Tuffaha M, Koren D, Levitsky LL. Management of Diabetic Ketoacidosis in Children and Adolescents with Type 1 Diabetes Mellitus. Paediatr Drugs. 2020 Aug;22(4):357-367. doi: 10.1007/s40272-020-00397-0. PMID: 32449138.
* Kordonouri O, Kerner W. [Type 1 diabetes: an update]. Internist (Berl). 2021 Jun;62(6):627-637. doi: 10.1007/s00108-021-01009-w. Epub 2021 Apr 7. PMID: 33825933; PMCID: PMC8024935.
* Toschi E, Atakov-Castillo A, Slyne C, Munshi M. Closed-Loop Insulin Therapy in Older Adults with Type 1 Diabetes: Real-World Data. Diabetes Technol Ther. 2022 Feb;24(2):140-142. doi: 10.1089/dia.2021.0311. Epub 2021 Oct 28. PMID: 34609917; PMCID: PMC8817701.
* Shah VN, Peters AL, Umpierrez GE, Sherr JL, Akturk HK, Aleppo G, Bally L, Cengiz E, Cinar A, Dungan K, Fabris C, Jacobs PG, Lal RA, Mader JK, Masharani U, Prahalad P, Schmidt S, Zijlstra E, Ho CN, Ayers AT, Tian T, Aaron RE, Klonoff DC. Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System. J Diabetes Sci Technol. 2025 Jan;19(1):191-216. doi: 10.1177/19322968241291512. Epub 2024 Nov 8. PMID: 39517127; PMCID: PMC11571606.
* Ebrahimpour Y, Khatami S, Saffar M, Fereidouni A, Biniaz Z, Erfanian N, Fereidouni M. A Comprehensive Review of Novel Advances in Type 1 Diabetes Mellitus. J Diabetes. 2025 Aug;17(8):e70120. doi: 10.1111/1753-0407.70120. PMID: 40765373; PMCID: PMC12326085.
* Jerram ST, Yang JHM, Williams E, Domingo-Vila C, Liu YF, Peakman M, Leslie RD, Tree T. Subcutaneous Abatacept in New Onset Type 1 Diabetes: Clinical and Immunological Effects. Diabetes Metab Res Rev. 2025 Sep;41(6):e70074. doi: 10.1002/dmrr.70074. PMID: 40790833; PMCID: PMC12340168.
* Ziegler AG, Cengiz E, Kay TWH. The future of type 1 diabetes therapy. Lancet. 2025 Oct 4;406(10511):1520-1534. doi: 10.1016/S0140-6736(25)01438-2. Epub 2025 Sep 19. PMID: 40983070.
* You L, Parikh HM, Triolo TM, Ferrat LA, Templeman EL, Oram RA, Gottlieb PA, Rich SS, Onengut-Gumuscu S, Steck AK, Krischer J, Redondo MJ. Genetic Predictors of Response to Oral Insulin for Type 1 Diabetes Prevention. Diabetes Care. 2026 Feb 1;49(2):344-351. doi: 10.2337/dc25-2006. PMID: 41364459; PMCID: PMC12824796.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.